Why the form of omega-3 you feed determines whether it works

Most omega-3 supplementation in horses starts with the right intention and a form that doesn't reliably reach the tissues where it's expected to act.

 

If you have looked into omega-3 for your horse, you have almost certainly encountered linseed. It is the most widely used source in equine feeding, it has a good reputation, and there is genuine logic behind it. Linseed contains alpha-linolenic acid — ALA — which is the plant-based form of omega-3. It is a real nutrient, and it does real things.

The problem is not what linseed contains. The problem is what happens next.

The step most people don't know about

ALA is not the form of omega-3 that the body incorporates directly into tissue. Before it can be used in cell membranes — in joints, skin, respiratory tissue, and elsewhere — it must first be converted into longer-chain forms: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

That conversion happens inside the horse. And it is where the system runs into difficulty.

The conversion from ALA to EPA and DHA requires multiple enzymatic steps. Those enzymes are shared with the processing of omega-6 fatty acids, which are abundant in most modern equine diets. The two pathways compete for the same resources, and omega-6 tends to win. The result is that only a limited proportion of ALA progresses through to EPA and DHA — and the proportion that does is not consistent or predictable.

This is not a minor inefficiency. Published equine studies have identified intake levels at which plasma DHA begins to change measurably — and in studies where ALA has been increased, EPA levels can sometimes be raised, but DHA typically does not change meaningfully, even when ALA intake increases substantially.

For many horses, this goes unnoticed, because increasing ALA does not produce a clear or immediate change. The diet looks the same. The supplement is being fed. The constraint is invisible.

Feeding more linseed does not reliably solve this. The constraint is in the pathway, not in the amount being fed.

Why DHA is the molecule that matters most

DHA is the fatty acid that accumulates most significantly in cell membranes in many of the tissues where omega-3 is expected to have an effect — joint fluid, respiratory epithelium, skin, and blood. It is incorporated into those membranes over time and influences how cells signal, including how they respond to inflammation. EPA plays a role in signalling too, particularly in the early stages of the inflammatory response. But DHA is the form that accumulates in tissue, and it is the one that research in horses has most consistently failed to raise through ALA supplementation.

If DHA is not reaching those tissues in meaningful amounts, the downstream effects are constrained regardless of how much omega-3 is being fed. The input is present. The output is not.

The only way to resolve a conversion constraint is to bypass it.

What changes when you remove the conversion step

EPA and DHA can be provided directly, without depending on the horse to produce them from ALA. The source is algae — the original source of all marine omega-3. Fish are rich in EPA and DHA because they eat algae, or eat animals that do. Going directly to algae removes the intermediary entirely.

When EPA and DHA are provided in this form, the question changes. It is no longer whether the horse can convert enough ALA. It becomes whether the dose is sufficient and whether it is maintained for long enough.

Those are more tractable questions — and they have more interpretable answers.

Why dose and time both matter

Published equine studies have identified intake levels at which DHA begins to produce measurable changes in plasma composition. Below that level, effects are limited or absent. Above it, meaningful differences appear.

Many supplements do not reach this level. This is where most fail — not because the molecule is wrong in principle, but because the amount being delivered is insufficient to move the system.

Reaching the threshold is necessary, but it is not the whole picture.

EPA and DHA do not act immediately. They are incorporated into cell membranes gradually, and that process takes time. Plasma DHA begins to rise within four to six weeks of consistent supplementation. Tissue incorporation continues beyond that. Observable effects follow that timeline — which means short supplementation periods often end before the process has had time to complete.

The requirement is not just the right dose. It is the right dose, maintained consistently, for long enough to allow incorporation to occur.

What this means in practice

Three conditions determine whether omega-3 supplementation is likely to work: the form being supplied, the dose being delivered, and the duration over which it is maintained.

If the form is ALA, the conversion constraint means the first condition is uncertain from the outset. If the dose is below the level at which measurable change occurs, the second condition is not met regardless of form. If the duration is too short, the third condition is not met regardless of the first two.

Once those three variables are clear, the structure of an effective protocol becomes more defined.

The Synaxis Core 90-Day Protocol is built around all three — direct EPA and DHA from algae, at a dose set above the published threshold, over a period sufficient for tissue incorporation to occur.

That is the structure the evidence points to.